Business Context and Reporting Period
This Form 6-K filing by Scinai Immunotherapeutics Ltd. covers the month of May 2024. The report serves to disseminate a press release issued on May 6, 2024, which announced the publication of the company's financial statements for the fiscal year ended December 31, 2023, and the concurrent filing of its Annual Report on Form 20-F.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced FY 2023 financial statements and the Annual Report on Form 20-F, which are not included in the body of this Form 6-K.
Material Changes
The document does not detail specific material changes in financial performance or operations compared to prior periods. It solely references the availability of the FY 2023 results and a business update provided in the attached press release.
Guidance, Outlook, and Risks
The filing indicates that a business update was provided in the press release dated May 6, 2024, but the text of this update, including any guidance, outlook, management commentary, or specific risks, is not present in this document. The filing incorporates the press release by reference into the company's Registration Statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Review the attached Press Release (Exhibit 99.1) for the specific FY 2023 financial results and business update.
- Access the Annual Report on Form 20-F for detailed audited financial statements and comprehensive risk factors.
- Verify the incorporation of this report into the company's active Registration Statements (File Nos. 333-271293, 333-239344, 333-274078, and 333-276767).